BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38232131)

  • 1. Discovery of
    Yang L; Hu X; Lu Y; Xu R; Xu Y; Ma W; Alam MS; Zhang T; Chai X; Lei Y; Ye Q; Dong X; Kang Y; Che J; Hou T; Li D
    J Med Chem; 2024 Feb; 67(3):1914-1931. PubMed ID: 38232131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the development of DprE1 inhibitors using AI/CADD approaches.
    Chen K; Xu R; Hu X; Li D; Hou T; Kang Y
    Drug Discov Today; 2024 Jun; 29(6):103987. PubMed ID: 38670256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors.
    Balabon O; Pitta E; Rogacki MK; Meiler E; Casanueva R; Guijarro L; Huss S; Lopez-Roman EM; Santos-Villarejo Á; Augustyns K; Ballell L; Aguirre DB; Bates RH; Cunningham F; Cacho M; Van der Veken P
    J Med Chem; 2020 May; 63(10):5367-5386. PubMed ID: 32342688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel DprE1 inhibitors via computational bioactivity fingerprints and structure-based virtual screening.
    Hu XP; Yang L; Chai X; Lei YX; Alam MS; Liu L; Shen C; Jiang DJ; Wang Z; Liu ZY; Xu L; Wan KL; Zhang TY; Yin YL; Li D; Cao DS; Hou TJ
    Acta Pharmacol Sin; 2022 Jun; 43(6):1605-1615. PubMed ID: 34667293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a Chemical Inhibitor with a Novel Scaffold Targeting Decaprenylphosphoryl-β-D-Ribose Oxidase (DprE1).
    Matsunaga T; Monobe K; Aoki S
    Infect Disord Drug Targets; 2023; 23(5):e090323214508. PubMed ID: 36892121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virtual Screening of Small Molecular Inhibitors against DprE1.
    Zhang G; Guo S; Cui H; Qi J
    Molecules; 2018 Feb; 23(3):. PubMed ID: 29495447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.
    Panda M; Ramachandran S; Ramachandran V; Shirude PS; Humnabadkar V; Nagalapur K; Sharma S; Kaur P; Guptha S; Narayan A; Mahadevaswamy J; Ambady A; Hegde N; Rudrapatna SS; Hosagrahara VP; Sambandamurthy VK; Raichurkar A
    J Med Chem; 2014 Jun; 57(11):4761-71. PubMed ID: 24818517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis.
    Chikhale RV; Barmade MA; Murumkar PR; Yadav MR
    J Med Chem; 2018 Oct; 61(19):8563-8593. PubMed ID: 29851474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure, dynamics, and interaction of Mycobacterium tuberculosis (Mtb) DprE1 and DprE2 examined by molecular modeling, simulation, and electrostatic studies.
    Bhutani I; Loharch S; Gupta P; Madathil R; Parkesh R
    PLoS One; 2015; 10(3):e0119771. PubMed ID: 25789990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of DprE1 inhibitors for tuberculosis through integrated in-silico approaches.
    Dash S; Rathi E; Kumar A; Chawla K; Kini SG
    Sci Rep; 2024 May; 14(1):11315. PubMed ID: 38760437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis.
    Foo CS; Lechartier B; Kolly GS; Boy-Röttger S; Neres J; Rybniker J; Lupien A; Sala C; Piton J; Cole ST
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6451-6459. PubMed ID: 27527085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure based pharmacophore modelling approach for the design of azaindole derivatives as DprE1 inhibitors for tuberculosis.
    Kb S; Kumari A; Shetty D; Fernandes E; Dv C; Jays J; Murahari M
    J Mol Graph Model; 2020 Dec; 101():107718. PubMed ID: 32949960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic molecules as DprE1 inhibitors: A patent review.
    Imran M; A S A; Thabet HK; Abida ; Afroz Bakht M
    Expert Opin Ther Pat; 2021 Aug; 31(8):759-772. PubMed ID: 33709862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis.
    Makarov V; Neres J; Hartkoorn RC; Ryabova OB; Kazakova E; Šarkan M; Huszár S; Piton J; Kolly GS; Vocat A; Conroy TM; Mikušová K; Cole ST
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4446-52. PubMed ID: 25987616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.
    Neres J; Hartkoorn RC; Chiarelli LR; Gadupudi R; Pasca MR; Mori G; Venturelli A; Savina S; Makarov V; Kolly GS; Molteni E; Binda C; Dhar N; Ferrari S; Brodin P; Delorme V; Landry V; de Jesus Lopes Ribeiro AL; Farina D; Saxena P; Pojer F; Carta A; Luciani R; Porta A; Zanoni G; De Rossi E; Costi MP; Riccardi G; Cole ST
    ACS Chem Biol; 2015 Mar; 10(3):705-14. PubMed ID: 25427196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2,6-Disubstituted 7-(naphthalen-2-ylmethyl)-7H-purines as a new class of potent antitubercular agents inhibiting DprE1.
    Finger V; Kucera T; Kafkova R; Muckova L; Dolezal R; Kubes J; Novak M; Prchal L; Lakatos L; Andrs M; Hympanova M; Marek J; Kufa M; Spiwok V; Soukup O; Mezeiova E; Janousek J; Nevosadova L; Benkova M; Kitson RRA; Kratky M; Bősze S; Mikusova K; Hartkoorn R; Roh J; Korabecny J
    Eur J Med Chem; 2023 Oct; 258():115611. PubMed ID: 37421887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase.
    Landge S; Mullick AB; Nagalapur K; Neres J; Subbulakshmi V; Murugan K; Ghosh A; Sadler C; Fellows MD; Humnabadkar V; Mahadevaswamy J; Vachaspati P; Sharma S; Kaur P; Mallya M; Rudrapatna S; Awasthy D; Sambandamurthy VK; Pojer F; Cole ST; Balganesh TS; Ugarkar BG; Balasubramanian V; Bandodkar BS; Panda M; Ramachandran V
    Bioorg Med Chem; 2015 Dec; 23(24):7694-710. PubMed ID: 26643218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationship mediated molecular insights of DprE1 inhibitors: A Comprehensive Review.
    Dash S; Rathi E; Kumar A; Chawla K; Joseph A; Kini SG
    J Biomol Struct Dyn; 2024 Aug; 42(12):6472-6522. PubMed ID: 37395797
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Borthwick JA; Alemparte C; Wall I; Whitehurst BC; Argyrou A; Burley G; de Dios-Anton P; Guijarro L; Monteiro MC; Ortega F; Suckling CJ; Pichel JC; Cacho M; Young RJ
    J Med Chem; 2020 Mar; 63(5):2557-2576. PubMed ID: 31922409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.